Gujarat Themis Biosyn Limited has secured shareholder approval to raise capital through a Qualified Institutions Placement (QIP) of equity shares. The special resolution was passed with 99.98% of votes in favour, authorizing the company to issue shares to qualified institutional buyers. This approval enables the company to access funds from institutional investors to support its financial objectives.

The voting process was conducted via remote e-voting, managed by Central Depository Services (India) Limited (CDSL). The e-voting period commenced on June 9, 2026, and concluded on July 8, 2026. A total of 79,477,366 votes were cast in favour of the resolution, while 18,941 votes were cast against it. The resolution required a special majority, which was comfortably met.

Voting Breakdown

The voting results were categorized by shareholder groups, with the promoter and promoter group casting 76,557,741 votes in favour, representing 100% of their polled votes. Public institutions and non-institutional shareholders also supported the resolution, with 98.54% and 99.98% of their respective votes in favour.

Procedural Details

The postal ballot notice was dispatched electronically to shareholders on June 8, 2026. Advertisements regarding the completion of dispatch were published in the 'Western Times' (English and Gujarati editions) on June 9, 2026. The scrutinizer, CS Ketan Ravindra Shirwadkar of KRS AND CO., confirmed that the voting process was conducted in a fair and transparent manner.

The scrutinizer's report, dated July 9, 2026, validated the results and confirmed the resolution's passage. The company will now proceed with the QIP process, subject to regulatory approvals and market conditions. The detailed voting results and scrutinizer's report are available on the company's website.

Pharmaceutical Business Group (India) Limited has disclosed an indirect encumbrance over 5,12,40,000 equity shares of Gujarat Themis Biosyn Limited . This action follows the creation of a pledge and a non-disposal undertaking by Vividhmargi Investments Private Limited over its shareholding in Pharmaceutical Business Group (India) Limited. The encumbrance, reported to BSE Limited and National Stock Exchange of India Limited on July 3, 2026, arises pursuant to a Debenture Trust Deed dated June 25, 2026.

Details of the Encumbrance

Vividhmargi Investments Private Limited created a pledge over 25,24,245 equity shares and a non-disposal undertaking over 21,57,855 equity shares of Pharmaceutical Business Group (India) Limited. These shares represent 51% and 47.98% of the issued and paid-up share capital of the company, respectively. The agreements were executed in favor of CTL Trusteeship Limited, acting as the Debenture Trustee, under a Pledge Agreement-cum-Non-Disposal Undertaking dated June 28, 2026.

Impact on Shareholding

As Pharmaceutical Business Group (India) Limited holds 5,12,40,000 equity shares in Gujarat Themis Biosyn Limited, the encumbrances on the parent company result in an indirect encumbrance over 47.02% of the equity share capital of the target company. The total promoter shareholding in Gujarat Themis Biosyn Limited stands at 7,72,18,083 shares, with the encumbered shares constituting 66.36% of the promoter holding.

Debt Instrument Details

The encumbrance relates to unrated, unlisted, secured, redeemable non-convertible debentures issued by OSS Software Solutions Labs Private Limited. The value of the encumbered shares is Rs. 19,68,89,70,000, against an involved amount of Rs. 135,00,00,000, resulting in a security cover ratio of 1:14.58. The borrowed funds are intended for personal use by the promoters and PACs.